Acceleron Pharma Inc. (XLRN) has a consensus analyst rating of Buy, based on 26 analysts covering the stock. Of those, 18 recommend buying, 7 recommend holding, and 1 recommend selling.
The analyst consensus price target for XLRN is $150.00, representing a -16.1% downside from the current price of $178.75. Price targets range from a low of $139.00 to a high of $160.00.
